Literature DB >> 8181247

Investigating the capillary circulation of the foot with 99mTc-macroaggregated albumin: a prospective study in patients with diabetes and foot ulceration.

K T Moriarty1, A C Perkins, A M Robinson, M L Wastie, R B Tattersall.   

Abstract

Macroaggregated albumin has been used to assess capillary circulation for over 20 years. The aim of the present study was to use 99mTc-macroaggregated albumin (99mTc-MAA) perfusion scanning to assess capillary circulation in feet with ischaemic ulcers in patients with diabetes, and relate the appearances to outcome. Twenty-three patients with diabetes presented with a total of 41 neuroischaemic foot ulcers. Perfusion scanning was performed by direct femoral artery injection of approximately 400,000 particles of 99mTc-MAA and imaging with a gamma camera. Patients were followed prospectively for 3 months. Scans were graded independently by a radiologist who was unaware of the site of the ulcers. Significant associations were detected between a radiologist's assessment of increased tissue perfusion and complete healing after 3 months (p = 0.047) and poor tissue perfusion on the image and failure to heal (p = 0.0005). This technique may be useful in deciding whether to persist with conservative treatment in patients with diabetes and foot ulceration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8181247     DOI: 10.1111/j.1464-5491.1994.tb00224.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  2 in total

1.  An en bloc approach to CT perfusion for the evaluation of limb ischemia.

Authors:  Joe Barfett; Nivethan Velauthapillai; Christian Kloeters; David J Mikulis; Jeffrey D Jaskolka
Journal:  Int J Cardiovasc Imaging       Date:  2012-12       Impact factor: 2.357

2.  CT-perfusion in peripheral arterial disease - Correlation with angiographic and hemodynamic parameters.

Authors:  Bert-Ram Sah; Patrick Veit-Haibach; Klaus Strobel; Martin Banyai; Martin W Huellner
Journal:  PLoS One       Date:  2019-09-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.